RxSight, Inc. Educational and Product Announcements for AAO 2023

ALISO VIEJO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- November 2, 2023 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced educational opportunities and product updates at the American Academy of Ophthalmology (AAO) Annual Meeting on November 3 – 6 in San Francisco. These include three scientific poster presentations (PO005, PO457, PO050) and 15 booth presentations (booth #229). At these events, leading U.S.-based ophthalmologists are slated to discuss diverse topics, including maximizing clinical results using the Light Adjustable Lens™ (LAL®) across a broad range of patient profiles, integration of the adjustable lens workflow, and real-life case studies showing the impact of high-quality, customized LAL vision. For the full program of events taking place at AAO 2023, click here.

One of these presentations (by Steven Slade, MD, of Houston-based Slade & Baker Vision on November 4 at 10:30 a.m.) will report clinical results using the LAL+, a new addition to the LAL family that will become available in the first quarter of 2024. The LAL+ has a built-in optical feature that is designed to further extend the depth of focus before light treatments, while preserving the high-quality vision of the LAL already familiar to customers and patients.

RxSight’s reconfigured Light Delivery Device (LDD™) will also be on display during AAO. While providing the same functionality and outcomes as the standard LDD, this compact model has a smaller footprint to address global practice space constraints.

About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:
ir@rxsight.com


Primary Logo

More News

View More

Recent Quotes

View More
Symbol Price Change (%)
AMZN  229.28
+0.03 (0.01%)
AAPL  270.93
+1.93 (0.72%)
AMD  264.96
+6.95 (2.69%)
BAC  52.79
-0.08 (-0.15%)
GOOG  270.91
+2.48 (0.92%)
META  749.24
-2.21 (-0.29%)
MSFT  538.47
-3.60 (-0.67%)
NVDA  209.89
+8.86 (4.41%)
ORCL  272.48
-8.35 (-2.97%)
TSLA  463.08
+2.53 (0.55%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.